A simulation of warfarin maintenance dose requirement using a pharmacogenetic algorithm in an ethnically diverse cohort

2010 ◽  
Vol 7 (3) ◽  
pp. 319-325 ◽  
Author(s):  
Patrick Gladding ◽  
John Mackay ◽  
Irene Zeng ◽  
Ralph Stewart ◽  
Rishi Prabkahar ◽  
...  
2015 ◽  
Vol 21 ◽  
pp. 3577-3584 ◽  
Author(s):  
Xiaojuan Yan ◽  
Feng Yang ◽  
Hanyun Zhou ◽  
Hongshen Zhang ◽  
Jianfei Liu ◽  
...  

1995 ◽  
Vol 5 (6) ◽  
pp. 389-392 ◽  
Author(s):  
Hirokazu Furuya ◽  
Pedro Fernandez-Salguero ◽  
Wendy Gregory ◽  
Heather Taber ◽  
Annette Steward ◽  
...  

2008 ◽  
Vol 9 (9) ◽  
pp. 1331-1346 ◽  
Author(s):  
Hedi Schelleman ◽  
Nita A Limdi ◽  
Stephen E Kimmel

2021 ◽  
Vol 2021 ◽  
pp. 1-9
Author(s):  
Lihong Tian ◽  
Pingping Xiao ◽  
Bingrong Zhou ◽  
Yishan Chen ◽  
Lijuan Kang ◽  
...  

This meta-analysis was conducted to analyze the effect of NQO1 polymorphism on the warfarin maintenance dosage. Using strict inclusion and exclusion criteria, we searched PubMed, EMBASE, and the Cochrane Library for eligible studies published prior to July 7, 2021. The required data were extracted, and experts were consulted when necessary. Review Manager Version 5.4 software was used to analyze the relationship between NQO1 polymorphisms and the warfarin maintenance dosage. Four articles involving 757 patients were included in the meta-analysis. Patients who were NQO1 rs10517 G carriers (AG carriers or GG carriers) required a 48% higher warfarin maintenance dose than those who were AA carriers. Patients with NQO1 rs1800566 CT carriers required a 13% higher warfarin dose than those who were CC carriers, with no associations observed with the other comparisons of the NQO1 rs1800566 genotypes. However, the results obtained by comparing the NQO1 rs1800566 genotypes require confirmation, as significant changes in the results were found in sensitivity analyses. Our meta-analysis suggests that the NQO1 rs10517and NQO1 rs1800566 variant statuses affect the required warfarin maintenance dose.


1992 ◽  
Vol 52 (1) ◽  
pp. 42-49 ◽  
Author(s):  
Aharon Lubetsky ◽  
Uri Seligsohn ◽  
David Ezra ◽  
Hillel Halkin

Sign in / Sign up

Export Citation Format

Share Document